142 related articles for article (PubMed ID: 37927219)
1. A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment.
Obaru C; Kimura T; Yamamura M; Kuriyama H; Kashiwada-Nakamura K; Mizuhashi S; Matsumura T; Watanabe T; Inoue T; Fukushima S
J Dermatol; 2024 Apr; 51(4):e115-e117. PubMed ID: 37927219
[No Abstract] [Full Text] [Related]
2. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
3. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.
Demarez B; Eté M; David L; Quiles N; Archier E
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e688-e689. PubMed ID: 35398936
[No Abstract] [Full Text] [Related]
4. What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead?
Rutkowski P; Rogala P
Expert Opin Pharmacother; 2023; 24(10):1101-1103. PubMed ID: 37144819
[No Abstract] [Full Text] [Related]
5. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.
Kim DY; Swetter SM; Huhmann L; Dizon MP; Ferguson JM; Osborne TF; Spence AC; Ziad A; Fillmore N; Hartman RI
J Am Acad Dermatol; 2024 Mar; 90(3):620-623. PubMed ID: 37924953
[No Abstract] [Full Text] [Related]
7. BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
Carrabba NV; Siliezar PD; Laylani N; Lee AG
Can J Ophthalmol; 2023 Dec; 58(6):e251-e253. PubMed ID: 37545048
[No Abstract] [Full Text] [Related]
8. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
9. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Ohuchi K; Hashimoto A; Aiba S
J Dermatol; 2020 Jun; 47(6):654-657. PubMed ID: 32293049
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
Okuma T; Furudate S; Kambayashi Y; Hashimoto A; Aiba S; Fujimura T
J Dermatol; 2021 Sep; 48(9):1419-1422. PubMed ID: 34002878
[TBL] [Abstract][Full Text] [Related]
11. Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.
Marani A; Gioacchini H; Paolinelli M; Offidani A; Campanati A
Expert Opin Drug Metab Toxicol; 2023; 19(8):555-567. PubMed ID: 37659065
[TBL] [Abstract][Full Text] [Related]
12. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
Amagai R; Fujimura T; Yamazaki E; Takahashi M; Tamabuchi E; Kambayashi Y; Hashimoto A; Hashimoto K; Asano Y
J Dermatol; 2024 Jun; 51(6):854-857. PubMed ID: 38111371
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
15. Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
Sada I; Harada Y; Hiyama T; Mizukami M; Kan T; Kawai M; Kiuchi Y
Melanoma Res; 2023 Dec; 33(6):539-546. PubMed ID: 37788106
[TBL] [Abstract][Full Text] [Related]
16. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
17. Tumor lysis syndrome induced by BRAF/MEK double blockade in a patient with metastatic melanoma: A first case report.
Tachibana K; Ohe S; Tanaka M; Maniwa T; Isei T
J Dermatol; 2021 Jul; 48(7):e324-e326. PubMed ID: 33990995
[No Abstract] [Full Text] [Related]
18. Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF/MEK inhibitors.
Oya K; Ishizuki S; Yasunaga S; Fujisawa Y; Nomura T
J Dermatol; 2024 Mar; 51(3):e61-e62. PubMed ID: 37904611
[No Abstract] [Full Text] [Related]
19. Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens.
Le Goubey JB; Sassier M; Nakouri I; De Pontville M; Césaire L; Aide N; Kottler D
Melanoma Res; 2023 Apr; 33(2):159-161. PubMed ID: 36815470
[No Abstract] [Full Text] [Related]
20. [Subretinal fluid associated with MEK and BRAF inhibitors].
Attia R; Comet A; Stolowy N; Fitoussi R; Michel T; Denis D; David T
J Fr Ophtalmol; 2022 Nov; 45(9):1091-1092. PubMed ID: 35908992
[No Abstract] [Full Text] [Related]
[Next] [New Search]